Ruijter E - Search Results

1

Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell carcinoma.

Shimazui T, Oosterwijk E, Akaza H, Bringuier P, Ruijter E, van Berkel H, Wakka JO, van Bokhoven A, Debruyne FM, Schalken JA. Shimazui T, et al. Among authors: ruijter e. Clin Cancer Res. 1998 Oct;4(10):2419-24. Clin Cancer Res. 1998. PMID: 9796973

2

Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma.

Shimazui T, Bringuier PP, van Berkel H, Ruijter E, Akaza H, Debruyne FM, Oosterwijk E, Schalken JA. Shimazui T, et al. Among authors: ruijter e. Int J Cancer. 1997 Oct 21;74(5):523-8. doi: 10.1002/(sici)1097-0215(19971021)74:5<523::aid-ijc8>3.0.co;2-5. Int J Cancer. 1997. PMID: 9355975

3

Alterations in expression of cadherin-6 and E-cadherin during kidney development and in renal cell carcinoma.

Shimazui T, Oosterwijk-Wakka J, Akaza H, Bringuier PP, Ruijter E, Debruyne FM, Schalken JA, Oosterwijk E. Shimazui T, et al. Among authors: ruijter e. Eur Urol. 2000 Sep;38(3):331-8. doi: 10.1159/000020302. Eur Urol. 2000. PMID: 10940709

4

Cadherin switching in human prostate cancer progression.

Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ, Schalken JA. Tomita K, et al. Among authors: ruijter et. Cancer Res. 2000 Jul 1;60(13):3650-4. Cancer Res. 2000. PMID: 10910081

5

Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group.

Ruijter E, van de Kaa C, Aalders T, Ruiter D, Miller G, Debruyne F, Schalken J. Ruijter E, et al. Mod Pathol. 1998 Mar;11(3):276-81. Mod Pathol. 1998. PMID: 9521475

6

Detection of abnormal E-cadherin expression by simulated prostate biopsy.

Ruijter ET, Werahera PN, van de Kaa CA, Stewart JS, Schalken JA, Miller GJ. Ruijter ET, et al. J Urol. 1998 Oct;160(4):1368-71; discussion 1371-2. J Urol. 1998. PMID: 9751355

7

Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group.

Ruijter ET, Miller GJ, Aalders TW, van de Kaa CA, Schalken JA, Debruyne FM, Boon ME. Ruijter ET, et al. J Pathol. 1997 Nov;183(3):369-75. doi: 10.1002/(SICI)1096-9896(199711)183:3<369::AID-PATH929>3.0.CO;2-9. J Pathol. 1997. PMID: 9422995

8

Tenascin-C expression in prostatic intraepithelial neoplasia (PIN): a marker of progression?

Xue Y, Smedts F, Latijnhouwers MA, Ruijter ET, Aalders TW, de la Rosette JJ, Debruyne FM, Schalken JA. Xue Y, et al. Among authors: ruijter et. Anticancer Res. 1998 Jul-Aug;18(4A):2679-84. Anticancer Res. 1998. PMID: 9703928

9

Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications.

Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. Ruijter ET, et al. J Pathol. 1996 Nov;180(3):295-9. doi: 10.1002/(SICI)1096-9896(199611)180:3<295::AID-PATH663>3.0.CO;2-W. J Pathol. 1996. PMID: 8958808

10

Molecular genetics and epidemiology of prostate carcinoma.

Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Ruijter E, et al. Endocr Rev. 1999 Feb;20(1):22-45. doi: 10.1210/edrv.20.1.0356. Endocr Rev. 1999. PMID: 10047972 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

116 results

Search Page

Filters